• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Please someone Explain !

The ‘directional’ nature of the Rabid...er Rapid reports is a joke. Also the continued ‘it will even out next month or next incentive period’ has become a punchline.